Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Complete the form below to unlock access to ALL audio articles.
Ipsogen SAS has announced the signature of an exclusive agreement with Warnex Inc., a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors.
According to the terms of the agreement, Ipsogen grants Warnex exclusive rights, for the Canadian territory, to market a service for the diagnosis and the classification of a group of leukemias.
“Identifying and commercializing cancer biomarkers carrying high value medical information is the core business of Ipsogen’s development strategy,” said Vincent Fert, President and CEO of Ipsogen.
“The medical community is now eager to integrate the JAK2 test into clinical practice. Ipsogen has recently launched the test both in the form of a product and a licensing program to react rapidly to these urgent medical needs. Warnex, with its strong position in the Canadian molecular diagnostic services market, is the ideal partner to help Ipsogen establish its leadership in Canada.”
The service is based on the analysis of variations in the JAK2 gene, for which Ipsogen has exclusive worldwide intellectual property rights. A high proportion of patients with myeloproliferative disorders (MPD; polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis) carry a dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2.
This work published in a 2005 issue of Nature by the INSERM team of Dr. Vainchenker (Institut Gustave Roussy, Paris) provides breakthrough progress for the molecular classification and the diagnosis of myeloproliferative disorders.
